CY1120921T1 - Τροποποιημενοι τελεστες αιματος περιλαμβανοντας ενα χαμηλου βαθμου υδατοδιαλυτο πολυμερες - Google Patents

Τροποποιημενοι τελεστες αιματος περιλαμβανοντας ενα χαμηλου βαθμου υδατοδιαλυτο πολυμερες

Info

Publication number
CY1120921T1
CY1120921T1 CY181100982T CY181100982T CY1120921T1 CY 1120921 T1 CY1120921 T1 CY 1120921T1 CY 181100982 T CY181100982 T CY 181100982T CY 181100982 T CY181100982 T CY 181100982T CY 1120921 T1 CY1120921 T1 CY 1120921T1
Authority
CY
Cyprus
Prior art keywords
ceremonies
soluble polymers
low grade
grade water
modified blood
Prior art date
Application number
CY181100982T
Other languages
English (en)
Inventor
Peter Turecek
Juergen Siekmann
Hanspeter Rottensteiner
Original Assignee
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH filed Critical Baxalta GmbH
Publication of CY1120921T1 publication Critical patent/CY1120921T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται, γενικά, με υλικά και μεθόδους για την παρασκευή τροποποιημένων τελεστών αίματος οι οποίοι έχουν χαμηλά επίπεδα μορίων υδατοδιαλυτών πολυμερών συζευγμένων στον τελεστή αίματος αλλά εκδηλώνουν βιολογική δραστηριότητα παρόμοια ως προς ή καλύτερη από μόρια έχοντας έναν υψηλότερο αριθμό οντοτήτων υδατοδιαλυτών πολυμερών.
CY181100982T 2008-10-17 2018-09-24 Τροποποιημενοι τελεστες αιματος περιλαμβανοντας ενα χαμηλου βαθμου υδατοδιαλυτο πολυμερες CY1120921T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10642408P 2008-10-17 2008-10-17
PCT/US2009/061023 WO2010045568A1 (en) 2008-10-17 2009-10-16 Modified blood factors comprising a low degree of water soluble polymer

Publications (1)

Publication Number Publication Date
CY1120921T1 true CY1120921T1 (el) 2019-12-11

Family

ID=41650072

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100982T CY1120921T1 (el) 2008-10-17 2018-09-24 Τροποποιημενοι τελεστες αιματος περιλαμβανοντας ενα χαμηλου βαθμου υδατοδιαλυτο πολυμερες

Country Status (19)

Country Link
US (4) US20100099616A1 (el)
EP (3) EP2349342B1 (el)
JP (2) JP5785872B2 (el)
KR (2) KR101929641B1 (el)
AU (1) AU2009305612B2 (el)
BR (1) BRPI0920259A8 (el)
CA (1) CA2738679A1 (el)
CY (1) CY1120921T1 (el)
DK (1) DK2349342T3 (el)
ES (1) ES2692172T3 (el)
HR (1) HRP20181454T1 (el)
HU (1) HUE039906T2 (el)
LT (1) LT2349342T (el)
MX (1) MX2011004085A (el)
NZ (1) NZ592688A (el)
PL (1) PL2349342T3 (el)
PT (1) PT2349342T (el)
SI (1) SI2349342T1 (el)
WO (1) WO2010045568A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2744370C2 (ru) * 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP2013532176A (ja) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
IN2014CN02448A (el) 2011-09-23 2015-06-19 Novo Nordisk As
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
PL3177317T3 (pl) 2014-08-04 2020-07-27 Csl Limited Formulacja czynnika viii
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
JP6552286B2 (ja) * 2015-06-05 2019-07-31 公立大学法人奈良県立医科大学 凝固第ｖｉｉｉ因子の複合体形成能に関する情報の取得方法および試薬キット
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6238908B1 (en) * 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
WO2004000366A1 (en) * 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
WO2004056852A2 (en) 2002-12-19 2004-07-08 Nektar Therapeutics Al, Corp. Cyanovirin variant-polymer conjugates
ES2911435T3 (es) * 2003-02-26 2022-05-19 Nektar Therapeutics Conjugados de polímero-resto de Factor VIII
CA2519092C (en) * 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
KR101100059B1 (ko) * 2004-06-30 2011-12-29 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
KR101654011B1 (ko) * 2004-11-12 2016-09-05 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
DK1835938T3 (da) * 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
EP1893230A2 (en) * 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
JP2009532351A (ja) 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第ｖｉｉｉ因子
PT2101821E (pt) * 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
JP5702066B2 (ja) 2006-12-27 2015-04-15 ネクター セラピューティクス 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体

Also Published As

Publication number Publication date
EP3620177A1 (en) 2020-03-11
PL2349342T3 (pl) 2019-01-31
KR20110071012A (ko) 2011-06-27
JP2015110676A (ja) 2015-06-18
NZ592688A (en) 2012-12-21
US20190160178A1 (en) 2019-05-30
KR101929641B1 (ko) 2018-12-14
SI2349342T1 (sl) 2018-10-30
JP2012505917A (ja) 2012-03-08
US20160199503A1 (en) 2016-07-14
JP5785872B2 (ja) 2015-09-30
HRP20181454T1 (hr) 2018-12-14
AU2009305612A1 (en) 2010-04-22
EP2349342A1 (en) 2011-08-03
EP3437661A1 (en) 2019-02-06
BRPI0920259A8 (pt) 2017-09-19
ES2692172T3 (es) 2018-11-30
PT2349342T (pt) 2018-10-26
KR20160103173A (ko) 2016-08-31
AU2009305612B2 (en) 2015-05-21
DK2349342T3 (en) 2018-10-08
LT2349342T (lt) 2018-10-10
HUE039906T2 (hu) 2019-02-28
CA2738679A1 (en) 2010-04-22
EP2349342B1 (en) 2018-06-27
WO2010045568A1 (en) 2010-04-22
BRPI0920259A2 (pt) 2016-01-05
MX2011004085A (es) 2011-09-27
US20120076749A1 (en) 2012-03-29
US20100099616A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
CY1120921T1 (el) Τροποποιημενοι τελεστες αιματος περιλαμβανοντας ενα χαμηλου βαθμου υδατοδιαλυτο πολυμερες
CY1122687T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
CY1123693T1 (el) Παραγοντες rnai, συνθεσεις και μεθοδοι χρησης αυτων για τη θεραπευτικη αγωγη σχετιζομενων με τρανσθυρετινη (ttr) ασθενειων
CY1118472T1 (el) Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων
CY1118231T1 (el) Συνθεση λιποσωματος
EA201170038A1 (ru) Загруженные лекарственным средством полимерные наночастицы и способы их получения и применения
EA201290497A1 (ru) Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
BRPI0722061A2 (pt) Uso polímeros
EP2399940A3 (en) Modified macromolecules and methods of making and using thereof
WO2013101902A3 (en) Chromophoric polymer dots with narrow-band emission
CY1112469T1 (el) Μια il-2 μουτεϊνη για θεραπεια ή για προφυλαξη απο ενα αυτοανοσο νοσημα
CY1116006T1 (el) Η εξουδετερωση της δρασtικοτητας των cd95 διακοπτει τη διηθηση των κυτταρων γλοιοβλαστωματος in vivo
BRPI0718146A2 (pt) Dispositivos de infusão e métodos
CO6620039A2 (es) Composiciones de catalizador para producir poliolefinas de alt mz/mw
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
CY1112278T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους
BRPI0922382A2 (pt) "material de polímero à base de celulose".
MX345643B (es) Cubierta médica.
ATE503469T1 (de) Nanoteilchen zur abgabe von nukleinsäure
MX2009014279A (es) Cadenas laterales de ester de fenilo para incrementar la resortividad polimerica.
CY1119890T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1
BRPI1011422A2 (pt) composições de polímero, artigos fabricados a partir de rais composições, e métodos para moldar tais composições.
CY1120597T1 (el) Νεα χρηση
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.